Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Non-Deal Roadshow (May 2015)
21 slides from Genetic Signatures's roadshow presentation, May 25, 2015
Slide 1: ASX Announcement: Non-Deal Roadshow Presentation 25 May 2015
ASX ANNOUNCEMENT Non-Deal Roadshow Presentation 25 May 2015 Sydney, 25 May 2015: Genetic Signatures (ASX: GSS) is pleased to release a copy of the presentation that John Melki, PhD., Director & CEO and Robert Birrell, Director & CFO, will be delivering to investors during a non-deal roadshow in Adel
Slide 2: Genetic Signatures Investor Presentation May 2015
Genetic Signatures Investor Presentation May 2015
Slide 3: Disclaimer
DISCLAIMER This presentation was prepared by Genetic Signatures Limited known as “Genetic Signatures“, (“GSS” or “the Company”), in order to discuss its business with various interested parties. This presentation in its entirety has been released to the market via the Australian Securities Exchange
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS Genetic Signatures is a molecular diagnostics (MDx) company operating in the global IVD (in vitro diagnostics) industry. Primary focus on supplying major hospitals and pathology laboratories in testing for infectious diseases. § Products already available in Australia with GSS
Slide 5: Corporate Snapshot
CORPORATE SNAPSHOT Capital Structure ASX Code GSS Shares on Issue 72.9m Market Capitalisation $30.6m Share Price (at market close 25 May, 2015) $0.42 Directors & Chief Executive Nick Samaras Non-Executive Chairman John Melki Director & CEO Mike Aicher Executive Director - US Phillip Isaacs Non-Execu
Slide 6: Management & Board
MANAGEMENT & BOARD Nick Samaras § More than 20 years’ experience in the global life sciences industry, BSc (Hons), PhD, MBA, senior executive roles with Applied Biosystems and Perkin Elmer FAIM, FAICD Non-Executive § NHMRC Research Committee member 2006-12, Adjunct Professor La Chairman Trobe Univ
Slide 7: Management & Board
MANAGEMENT & BOARD Mike Aicher § More than 30 years of industry experience BSc, MBA § Previously CEO and founder of National Genetics Institute (NGI), Executive Director – acquired by Laboratory Corporation of America, Inc. (LabCorp) in U.S Operations) 2000 § Responsible for LabCorp’s Esoteric bu
Slide 8: Technology – 3Base™
TECHNOLOGY – 3BASE™ A transformational MDx technology enabling customers to identify a wider array of patient infections § GSS’ 3Base™ platform is a proprietary molecular technique which changes naturally occurring DNA and RNA sequences to reduce sequence variation between subtypes § Patent-protec
Slide 9: Technology – 3Base™
TECHNOLOGY – 3BASE™ Platform technology converts original 4-base microbial genome to 3-base, thereby reducing complexity in molecular testing. Applicable in testing for infectious diseases and chronic diseases including cancers 8
Slide 10: EasyScreen™ Testing Kits
EASYSCREEN™ TESTING KITS § GSS’ suite of EasyScreen™ products are used by major hospitals in Australia for detection of infectious diseases – more than 37,000 tests performed in FY14, and more than 40,000 in the nine months to end March 2015; § Products work with existing customer systems to deliv
Slide 11: EasyScreen™ Product Development Pathway
EASYSCREEN™ PRODUCT DEVELOPMENT PATHWAY Experimental & Analytical Validation Clinical & Regulatory Validation & Release (i) (ii) (iii) (iv) (i) (ii) (iii) (iv) Enteric Kits Respiratory MRSA STI Tuberculosis Meningitis Each product goes through extensive development and beta testing and adheres to ri
Slide 12: Targeting Critical Health
TARGETING CRITICAL HEALTH § Gastroenteritis is a major widespread clinical problem (16.8 million cases per annum in Australia alone) resulting in 250,000 visits to hospital emergency departments, 15,000 hospitalisations and 80 deaths) § GSS’ testing offers faster and more reliable diagnosis for be
Slide 13: Commercialisation in Key Global Markets
COMMERCIALISATION IN KEY GLOBAL MARKETS § Products have completed extensive customer validation in Australia over the past four years § High profile customers including Sydney’s Westmead Hospital, St. Vincent’s Hospital, Prince of Wales Hospital and Royal North Shore Hospital § Established operat
Slide 14: Commercialisation Progress
COMMERCIALISATION PROGRESS Australia § Currently in market with major hospital and pathology group customers § Testing for 22 causes of gastroenteritis § Testing for 15 causes of viral respiratory disease § Next new product in beta testing with customer Western Europe § Established operations i
Slide 15: Competitor Environment
COMPETITOR ENVIRONMENT Table 1 opposite explores the global competitive environment in which GSS operates for infectious disease products, focusing on enteric (otherwise known as or gastroenteritis) screening. Table 1 incorporates the major criteria utilised by global customers in assessing products
Slide 16: Case Study: Major Hospital, Sydney: Pilot Study 2013
Case Study: Major Hospital, Sydney, Australia: Pilot Study 2013 – EasyScreen™ vs Traditional METHODS: § Primary focus of this study was to assess the clinical utility of EasyScreen™ in detecting infectious agents in 279 patient samples as compared to their existing methods § Results generated in a
Slide 17: Case Study: St Vincent's Hospital (SydPath) Evaluation Study 2014
“I find that the fast turnaround time and the number of targets tested in the EasyScreenTM assays allow me to more rapidly identify highly infectious agents, potentially stopping the spread to other healthy individuals and thereby saving the health system money.” (Dr Damien Stark) Case Study: St Vin
Slide 18: Intellectual Property
INTELLECTUAL PROPERTY § The 3Base™ platform and products are protected by a strong patent portfolio, securing rights in the markets in which it chooses to operate. § Patent portfolio has been built over 13 years and patents granted in the major jurisdictions in which it operates or expects to oper
Slide 19: Summary
SUMMARY § EasyScreen™ Respiratory & Enteric Pathogen Detection Kits provide faster & more accurate screening for viral, bacterial and protozoan pathogens – tests are processed in hours instead of days, with fewer false positives and negatives § Products already available in Australia with GSS set
Slide 20: Milestones - Snapshot
MILESTONES - SNAPSHOT Achieved – CY 2015 § IPO § Continued sales growth of enteric product line § Initial Revenues generated from second product line – Respiratory To lookout for – balance of CY 2015 § Continued sales growth § Additional EU distributorships § Release of third product line – MR
Slide 21: Contact
CONTACT: John Melki Chief Executive Officer john@geneticsignatures.com T: +61 2 9870 7580 www.geneticsignatures.com.au 20